Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Whysner et al
In its Complete Response Letter (CRL), the FDA cited undisclosed product quality and master filing issues for the infusion device, which is proprietary to the device manufacturer, according to Supernus announcement
Although the drug was found to be effective at reducing some cardiac serious adverse events (SAEs), the risk for DVT increased
First, it isnt approved for weight loss, so this would be an off-label use
Europol announced the results of Operation Shield IV, a six-month, 30-country effort targeting illegal sales of counterfeit and misused medicines and illicit doping substances in Europe
Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation
US$ 25.28
US$ 28.34
US$ 29.93
